Search
Nomacopan
go.drugbank.com/drugs/DB14991InvestigationalNomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Olaparib-bodipy FL
go.drugbank.com/drugs/DB16263InvestigationalOlaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).
DTX-101
go.drugbank.com/drugs/DB17699InvestigationalIt was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103] … DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.
Coagulin-B
go.drugbank.com/drugs/DB17703Experimental[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation
Retezorogant
go.drugbank.com/drugs/DB21592ExperimentalThe usage of the INN stem '-rogant' in the name indicates that Retezorogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist.
Revexepride
go.drugbank.com/drugs/DB20324InvestigationalThe usage of the INN stem '-pride' in the name indicates that Revexepride is a sulpiride derivative and analogue. … Revexepride is under investigation in clinical trial NCT01472939 (Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)).
Levcromakalim
go.drugbank.com/drugs/DB21154InvestigationalThe usage of the INN stem '-kalim' in the name indicates that Levcromakalim is a potassium channel activator, antihypertensive.
Luvometinib
go.drugbank.com/drugs/DB21696InvestigationalThe usage of the INN stem '-tinib' in the name indicates that Luvometinib is a tyrosine kinase inhibitor.
Pebezertinib
go.drugbank.com/drugs/DB21705InvestigationalThe usage of the INN stem '-ertinib' in the name indicates that Pebezertinib is a epidermal growth factor receptor (EGFR) inhibitor.
Inlexisertib
go.drugbank.com/drugs/DB21713InvestigationalThe usage of the INN stem '-sertib' in the name indicates that Inlexisertib is a serine/threonine kinase inhibitor.